A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation

Trial Profile

A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Apr 2017

At a glance

  • Drugs Paliperidone (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Acronyms REMISSIO
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 17 Mar 2017 Planned End Date changed from 1 Mar 2018 to 31 Mar 2018.
    • 17 Mar 2017 Planned End Date changed from 1 Mar 2018 to 31 Mar 2018.
    • 17 Mar 2017 Planned primary completion date changed from 1 Dec 2017 to 31 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top